Stefan Schreiber

14PUBLICATIONS
73CO-AUTHORS
Major global burdens of diseaseToxicology (incl. clinical toxicology)Medical biochemistry - proteins and peptides (incl. medical proteomics)Epidemiological methodsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jul 28, 2026
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments.

|Jul 21, 2026
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn's disease: post hoc results from the phase 3b SEQUENCE trial.

|Jun 26, 2026
Combined bowel urgency, clinical outcomes, and quality of life improvement in mirikizumab-treated ulcerative colitis: a step toward comprehensive disease management.

|Jun 15, 2026
Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany.

|Apr 15, 2026
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.

|Oct 06, 2025
Rise of precision medicine: can it deliver on its promise in IBD?

Stefan Schreiber, Konrad Aden, Florian Tran

Pageof 3

Frequent Collaborators

6 joint publications

Silvio Danese

4 joint publications

Stephen Hanauer

3 joint publications

Bruce E Sands

3 joint publications

Laurent Peyrin-Biroulet